A large fraction of the sequence variants of unknown significance or unclassified variants (UVs), including exonic variants, could be pathogenic by affecting mRNA splicing. The breast and ovarian cancer susceptibility gene BRCA1 exhibits a large spectrum of sequence variation but only two variants, both located in exon 18, have been shown experimentally to affect splicing regulatory elements. In the present study, we investigate the impact on splicing of the variant BRCA1 c.5434C>G (p.Pro1812Ala), identified in an ovarian cancer patient.
INTRODUCTION
Genetic counseling is often limited by lack of knowledge about the pathogenic role of a large fraction of germline sequence variations. These are usually referred to as variants of unknown significance or unclassified variants (UVs). These types of variants are especially problematic for the breast and ovarian cancer susceptibility gene, BRCA1, which exhibits a large spectrum of sequence variation. Among these variants, most of the missense changes identified in the BRCA1 gene, as well as many intronic sequence changes, are currently listed as UVs in the database of the Breast Cancer Information Core (BIC, http://research.nhgri.nih.gov/projects/bic).
Over the past ten years, it became clear that a large fraction of missense UVs could be deleterious by impacting pre-mRNA splicing. [1, 2] Exonic mutations alter either splice site sequences or splicing regulatory elements such as ESE (exonic splicing enhancer) or ESS (exonic splicing silencer). Most ESE elements promote exon inclusion by interacting with activating splicing factors, usually members of the serine/argine-rich protein family. In contrast, ESS elements play a role in splicing repression usually through the binding of proteins, mostly belonging to the heterogenous nuclear ribonucleoprotein (hnRNP) family.
Mutations in these cis-acting elements may induce abnormalities in pre-mRNA splicing, that could result either in the degradation of the mature aberrant mRNA by the nonsense mediated decay (NMD) pathway or in the production of an altered protein. [3] Here, we describe the characterization of the c.5434C>G (p.Pro1812Ala) variant found in the BRCA1 gene in a French ovarian cancer patient. This variant was previously identified in several families with breast and/or ovarian cancers and was reported as an UV but was not listed in the BIC database of BRCA mutations. [4] [5] [6] Because it co-segregates with the high risk phenotype at least in one family, [6] this variant was suspected to be deleterious.
considering the high degree of conservation across species of the proline at position 1812 and its location in the second BRCT (BRCA1 carboxyl terminal) domain. However, a previous study showed that the BRCA1 p.Pro1812Ala variant induces a modest decrease in the activity of the BRCA1 protein, based on a transcriptional transactivation assay. [6] More recently, the effects of this variant were also tested on structural integrity, protein stability and interaction with various phosphopeptides but these data were not sufficient to characterize this mutation as pathogenic. [7] Thus, the deleterious nature of this missense mutation was unclear at the protein level and this uncertainty prompted us to investigate its impact on pre-mRNA splicing. Here, we show that the BRCA1 c.5434C>G variant induces a major splicing defect, resulting in skipping of exon 23.
METHODS

Patient
The BRCA1 c.5434C>G variant tested in this study was detected in an index case selected from families undergoing genetic counseling in the Western French breast cancer genetics network. The criteria for diagnostic mutation screening of BRCA1/2 genes in patients were according to the current French recommendations. The patient gave signed informed consent.
Nomenclature
The DNA sequence numbering is based on the cDNA sequence for BRCA1 (NCBI RefSeq NM_007294), following the recommendations of the Human Genome Variation Society (HGVS, first position of the translation initiation codon ATG=1).
Genetic analysis
Patient peripheral blood samples were collected in EDTA tubes. Genomic DNA was isolated using an automated procedure (EZ1 DNA blood kit on biorobot EZ1 workstation, Qiagen, Hilden, Germany). Screening for BRCA1 and BRCA2 mutations was performed using denaturing High Performance Liquid Chromatography (dHPLC) or High Resolution Melting (HRM), followed by direct sequencing. Screening for BRCA1 and BRCA2 large rearrangements was performed using a combination of the multiplex ligation-dependent probe amplification (MLPA) and quantitative multiplex PCR of short fluorescent fragments (QMPSF) methods. 
RT-PCR analysis of patient blood RNA
Splicing minigene reporter assay
Generation of minigene constructs. The splicing minigene assay has been previously described. [12] [13] [14] Wild-type and mutant c.5434C>G BRCA1 exon 23, together with 236 bp of the 5' flanking intron and 202 bp of the 3' flanking intron, were amplified by PCR using forward primer (5'-GACCAGATCTATTAGCCAGGGGTGGTGGTA-3') and reverse primer (5'-GACCACGCGTCACCCCATGGAAACAGTTCA-3'), carrying 5' tails with BglII and
MluI restriction sites (underlined), respectively. After digestion with BglII and MluI, the PCR products were inserted into the intron of the two-exons pCAS1 splicing reporter minigene vector (Fig. 1B) . [12] [13] [14] Transfection and RT-PCR analysis. After identification by plasmid sequencing, the wild-type and mutant minigene constructs were transiently transfected into HeLa cells using 
ESE-dependent splicing assay
Generation of pcDNA-Dup constructs. BRCA1 exon 23 wild-type fragment c.5420-5449 was tested for the presence of ESE splicing regulatory sequences by using an ESE-dependent splicing assay. [12] Briefly, the exonic fragment was obtained by annealing complementary 
RESULTS
Identification of the BRCA1 c.5434C>G variant in an ovarian cancer patient
The patient was referred for genetic counseling, based on the diagnosis of ovarian cancer at 53 years and her family history. Her mother and maternal aunt were diagnosed with ovarian cancer at ages 53 and 65 years, respectively. Her paternal aunt was diagnosed with breast cancer at age 65 years. Using the Manchester scoring system, [15] prior probabilities of a pathogenic mutation were 51% in the BRCA1 gene and 32% in the BRCA2 gene. Based on this information, the genomic DNA of this patient was screened for germ-line mutations and large genomic rearrangements in both BRCA1 and BRCA2 genes. No genetic alteration was found in BRCA2. However, a C to G transvertion was identified at position c.5434 of BRCA1.
At the time of genetic counseling, this BRCA1 c.5434C>G variant was not listed in the BRCA1 mutation BIC database nor in the French database of BRCA1 mutation (Dr. Rosette Lidereau, personal communication). It was therefore considered as an unclassified variant. In order to assess the pathogenicity of this variant, partial segregation analysis was performed.
As the mother of the proband was deceased at the time of the analysis, her affected maternal aunt was tested and found to be a carrier of BRCA1 c.5434C>G. This observation suggested a germline transmission of the variant in the maternal branch, indicating that it could represent the disease causing mutation or a genetic marker linked to it.
The BRCA1 c.5434C>G variant is associated with abnormal splicing of BRCA1 mRNA in patient blood cells
In order to evaluate the consequence of the BRCA1 c.5434C>G sequence variant on BRCA1
pre-mRNA splicing, RT-PCR analysis was performed using total RNA extracted from peripheral lymphocytes of the proband and a control subject (Fig. 1A) . A single product with 1 the expected size (456 bp) was detected in the control subject and sequencing confirmed that it corresponds to the region covering exon 20 to the 3'UTR of the normal BRCA1 transcript, including exon 23 (Fig. 1A) . In contrast, the analysis of RNA from the patient carrying the BRCA1 c.5434C>G variant revealed the presence of an additional RT-PCR product with a smaller size (395 bp), expressed at a slightly lower level, that was identified by sequencing as an aberrant transcript lacking BRCA1 exon 23 (Fig. 1A) . Semi-quantitative analysis indicated that this RT-PCR product accounts for 35% of the total transcripts (data not shown).
Therefore, skipping of exon 23 in the transcript corresponding to the mutant allele could be incomplete, or the aberrant mRNA could be degraded in part by the NMD pathway.
Sequencing of the top band corresponding to the normal BRCA1 transcript showed a barely detectable signal from the mutant sequence, strongly suggesting that very low levels of normal mRNA were expressed from the mutant allele. This result demonstrates that the presence of the BRCA1 c.5434C>G variant is associated with a major splicing defect, resulting in the skipping of exon 23.
The BRCA1 c.5434C>G variant induces BRCA1 exon 23 skipping in a minigene splicing assay In order to test the hypothesis that this aberrant skipping of BRCA1 exon 23 was directly caused by the substitution C to G at position c.5434, the effect of the variant on splicing was assessed using a minigene splicing assay (Fig. 1B) . pCAS minigene constructs carrying either the wild-type or the mutant BRCA1 c.5434C>G exon 23 were transiently expressed in HeLa cells and the minigene transcripts were analyzed by RT-PCR (Fig. 1C) . Because the patient is heterozygous for the frequent SNP c.5407-193A>G (rs8176310, minor allele frequency:
0.456) located in intron 22, the wild-type and mutant c.5434C>G minigene constructs carried the G and A polymorphic nucleotides, respectively. All the processed RNA expressed from the wild-type BRCA1 exon 23 minigene retained BRCA1 exon 23, indicating that the less frequent G nucleotide at the intronic polymorphism rs8176310 has no negative effect on splicing. In contrast, the major spliced transcript expressed from the mutant BRCA1 c.5434C>G exon 23 minigene exhibits skipping of exon 23 (Fig. 1C) . Semi-quantitative analysis indicated that, in this monoallelic assay, 75% of the total transcripts have skipped exon 23 (data not shown). These data demonstrate that the variant BRCA1 c.5434C>G is directly responsible for a major splicing defect.
The BRCA1 region c.5420-5449 in the centre of exon 23 contains sequences with global enhancer properties, which are affected by the c.5434C>G mutation
The c.5434C>G variant is located in the centre (position +28) of the short exon 23 (61 bp) of the BRCA1 gene, in a region highly conserved at nucleotide level across species (Fig. 2) .
Nucleotide sequence conservation is particularly striking in a stretch of 6 amino acids with highly degenerate codons (IVVVQP). Such an exonic mutation, associated with exon skipping and located at distance from the splice sites, is likely to affect splicing regulatory elements. In order to determine if the BRCA1 exonic region affected by the c.5434C>G mutation contains a splicing enhancer element (ESE), we took advantage of an ESEdependent splicing assay (Fig. 3A) . [12] A ~30 bp fragment was inserted into the middle exon of a three-exon minigene under the control of a CMV promoter. The different minigenes were transiently expressed in HeLa cells and the splicing patterns of the minigene transcripts were analyzed by RT-PCR. Due to a weak 3' splice site, this middle exon is not recognized by the splicing machinery and therefore is excluded from the processed transcript, unless enhancer elements are inserted within its sequence. [12] As expected, the middle exon was included into the mature transcripts expressed from a positive control minigene (SF2/ASF-3x) carrying triplet of enhancer elements (ESE), known to bind to the splicing regulatory SR protein SF2/ASF (Fig. 3B) , whereas the middle exon without enhancer element was excluded from the mature transcripts expressed from minigenes without an inserted sequence (empty), or containing a randomly chosen intronic sequence derived from the BRCA2 intron 11 (BR2Int11) (Fig. 3B) . The wild-type c.5420-5449 segment of BRCA1 exon 23 was able to induce inclusion of the middle exon (Fig. 3B) , strongly suggesting that this specific region contains a sequence with enhancer properties. In contrast, the middle exon was excluded from the mature transcripts expressed from the minigene carrying the BRCA1 exon 23 c.5420-5449 region with the c.5434C>G mutation. This result indicates that the c.5434C>G variant induces skipping of BRCA1 exon 23 either by disrupting an enhancer element (ESE) or by creating a silencer element (ESS).
We also analyzed the impact on splicing of a reported SNP at the same position (BRCA1 c.5434C>T; rs1800751) by using the same ESE-dependent assay (Fig. 3B) . In contrast to the c.5434C>G mutation, the c.5434C>T variant had modest negative effect on the inclusion of the middle exon. This result suggests that the effect on splicing at position c.5434 is nucleotide-dependent.
Both exonic variants, BRCA1 c.5434C>G and c.5434C>T, were analyzed by using bioinformatics prediction programs, for possible splicing enhancer (ESE) disruption and silencer (ESS) creation. As shown in Table 1 , as determined using ESE finder [8, 9] b , as determined using hnRNPA1 experimental motif from HSF [11] c , the nucleotide underlined indicates the position of the mutation *, scores that differ significantly considering the threshold
DISCUSSION
We have shown, using patient RNA analyses and minigene splicing assays, that the BRCA1 variant c.5434C>G (p.Pro1812Ala) induces a major splicing defect, resulting in the skipping of exon 23. The amount of exon skipping was estimated at 75% in the monoallelic splicing minigene assay, a value that is consistent with the analysis of RT-PCR products obtained from patient blood cell RNA. Translation of the aberrant transcript is predicted to result in a protein with a premature stop codon, p.Gly1803GlnfsX11, which disrupts the second BRCT domain.
This functional region is essential for the tumor suppressor activity of the BRCA1 protein, as it is involved in DNA repair and transcriptional control. [16, 17] Altogether, these results strongly suggest that the mutation BRCA1 c.5434C>G induces the production of a nonfunctional protein, as a consequence of exon 23 skipping, and argue for its classification as a pathogenic mutation. This study adds to the growing list of examples indicating that missense changes, even those affecting extremely conserved amino-acid residues located in functional domains, should not be evaluated exclusively at protein level. [18] Over the past ten years, exonic mutations identified in genetic screening of several genes have been shown to induce exon skipping by altering splicing regulatory elements. [3] But, so far, in the BRCA1 gene, only two mutations, both located in exon 18, have been shown experimentally to affect splicing regulatory elements: the nonsense variant c.5080G>T
(p.Glu1694X) [19] [20] [21] and the missense variant c.5123C>T (p.Ala1708Glu). [22] We investigated the mechanism underlying the effect of the mutation BRCA1 c.5434C>G on splicing. Using an ESE-dependent splicing assay, we show that the central 30 nucleotide-long region of exon 23 encloses a sequence with global enhancer properties, which are strongly affected by the c.5434C>G mutation. In contrast, the c.5434C>T variant, which corresponds to a SNP without allele frequencies listed in the dbSNP database of NCBI, has little effect in the ESE-dependent splicing assay and its functional consequences are debated. [23] The bioinformatics predictions shown in Table I indicate, for both variants, a strong reduction of scores for two ESE elements and predict, only for the c.5434C>G variant, the generation of a new hnRNPA1 splicing silencer motif. Our data and these bioinformatics predictions suggest that the exonic variant BRCA1 c.5434C>G creates a sequence with silencer properties, predicted to bind the splicing repressor hnRNPA1. A similar model has been proposed to explain the impact on splicing of the nonsense BRCA1 c.5080G>T mutation, which causes exon 18 skipping [19] and was initially predicted to disrupt a splicing enhancer element for the SF2/ASF protein. [20] It has recently been shown that this variant creates a silencer element, which interacts with the inhibitory splicing factor hnRNPA1/A2 and DAZAP1. [21] The other variant in exon 18 of BRCA1 reported to induce exon skipping is the missense variant c.5123C>A, which is thought to increase the RNA binding of the splicing repressors hnRNPA1 and hnRNPH/F. [22] Similar models could explain the effect on exon 23 splicing of the BRCA1 c.5434C>G mutation. However, at this point, we cannot rule out other models, based on the inactivation of an ESE or on a combination of ESE inactivation and generation of an ESS. In the BRCA2 gene, exon skipping has been associated with the missense mutations c.8165C>G (p.Thr2722Arg) in exon 18 [24] and c.6853A>G (p.Ile2285Val) in exon 12 [25] , but the molecular bases of these splicing defects have not been described.
Retrospectively, one may ask if bioinformatics predictions could have pointed to the c.5434C>G variant as a splicing mutation. It should be noted that we initially decided to examine the effect of this variant on splicing not because of bioinformatics predictions, but because the available information on the functional consequences of this change at the protein level were inconclusive and family data suggested that it was directly or indirectly associated with the predisposition to breast/ovarian cancer.[6, and the present study] Most published evaluations of bioinformatics predictions of splicing defects deal with UVs that affect splice site changes, either by affecting 5' or 3' splice sites, or by creating or activating cryptic splice sites. These predictions are usually considered sensitive and rather specific. [26] On the other hand, bioinformatics predictions of the effects of UVs on exonic regulatory elements are much less reliable and lack specificity. [12, 27, 28] Therefore, bioinformatics analyses of exonic splicing regulatory elements need the addition of other criteria to improve specificity.
Strong sequence conservation at the nucleotide level could be among such additional criteria, as already suggested. [29, 30] Moreover, sequence variations in small size exons could be more prone to affect exonic splicing regulatory elements than those located in large size exons, [31] where compensatory effects may exist.
In summary, our results provide in vivo and ex vivo evidences that the BRCA1 c.5434C>G variant is pathogenic through a major skipping of exon 23. As is often the case with splicing mutations, the resulting defect is not complete, but was estimated to be present on about 75% of the transcripts from the mutant allele. This finding and the predicted deleterious consequences on the corresponding BRCA1 protein, together with segregation data from this family and from another family [6] places the c.5434C>G variant of BRCA1 into class 4, i.e. "Likely pathogenic" of the classification system that has been recently proposed by Plon et al. [32] In addition, analyses of the effect of this variant on exonic splicing regulatory elements contribute to a better understanding of the mechanisms underlying splicing regulation. Figure 3 
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